Mendes Raquel V, Ribeiro Joana M, Gouveia Helena, Rebelo de Almeida Cátia, Castillo-Martin Mireia, Brito Maria José, Canas-Marques Rita, Batista Eva, Alves Celeste, Sousa Berta, Gouveia Pedro, Ferreira Miguel Godinho, Cardoso Maria João, Cardoso Fatima, Fior Rita
Champalimaud Research, Champalimaud Foundation, Lisbon, Portugal.
Gustave Roussy, Département de Médecine Oncologique, Villejuif, France.
NPJ Precis Oncol. 2025 Apr 1;9(1):94. doi: 10.1038/s41698-025-00882-0.
Chemotherapy remains the mainstay in most high-risk breast cancer (BC) settings, with several equivalent options of treatment. However, the efficacy of each treatment varies between patients and there is currently no test to determine which option will be the most effective for each individual patient. Here, we developed a fast in-vivo test for BC therapy screening: the zebrafish patient-derived-xenograft model (zAvatars), where in-vivo results can be obtained in just 10 days. To determine the predictive value of the BC zAvatars we performed a preclinical study, where zAvatars were treated with the same therapy as the donor-patient and their response to therapy was compared. Our data show a 100% concordance (18 out of 18) between the zAvatar-test and the corresponding patient's clinical response to treatment. Altogether, our results suggest that the zAvatar model constitutes a promising in-vivo assay to optimize cancer treatments in a truly personalized manner.
化疗仍然是大多数高危乳腺癌（BC）治疗的主要手段，有几种等效的治疗方案。然而，每种治疗方法的疗效在患者之间存在差异，目前尚无测试方法来确定哪种方案对每个患者最有效。在此，我们开发了一种用于乳腺癌治疗筛选的快速体内测试：斑马鱼患者来源异种移植模型（zAvatars），该模型只需10天就能获得体内结果。为了确定BC zAvatars的预测价值，我们进行了一项临床前研究，用与供体患者相同的疗法治疗zAvatars，并比较它们对治疗的反应。我们的数据显示，zAvatar测试与相应患者的临床治疗反应之间的一致性为100%（18例中的18例）。总之，我们的结果表明，zAvatar模型构成了一种很有前景的体内试验，能够以真正个性化的方式优化癌症治疗。
